Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 7, 2011, Pages 1079-1083

  Soeda, Hiroshi ^a,b   Shimodaira, Hideki ^a,b   Ishioka, Chikashi ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anti EGFR antibody; Colorectal cancer; KRAS; Predictive biomarker

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CD16 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC GAMMA RECEPTOR IIIA; FC RECEPTOR IIA; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTITUMOR GENE; ARTICLE; CANCER RESISTANCE; COLORECTAL CANCER; DNA POLYMORPHISM; GENE MUTATION; HUMAN; METASTASIS; PATIENT SELECTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WILD TYPE;

EID: 80052756104     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683, 2009.
2. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006. (Pubitemid 44497237)
3. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
4. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006. (Pubitemid 44301348)
5. Li S, Schmitz KR, Jeffrey PD, et al: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311, 2005. (Pubitemid 40544648)
6. Hecht JR, Mitchell E, Neubauer MA, et al: Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16: 2205-2213, 2010.
7. Downward J: Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 3(1): 11-22, 2003.
8. Brink M, de Goeij AF, Weijenberg MP, et al: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710, 2003. (Pubitemid 36592405)
9. Egan SE and Weinberg RA: The pathway to signal achievement. Nature 365: 781-783, 1993. (Pubitemid 23341020)
10. Cutsem EV, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initialtreatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
11. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
12. Michaloglou C, Vredeveld LCW, Mooi WJ, et al: BRAFE600 in benign and malignant human tumours. Oncogene 27: 877-895, 2008.
13. Barault L, Veyrie N, Jooste V, et al: Mutations in RAS-MAPK, PI3K signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255-2259, 2008. (Pubitemid 351542328)
14. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
15. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.
16. Loupakis F, Ruzzo A, Cremolini C, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721, 2009.
17. Tol J, Nagtegaal ID, Punt CJ, et al: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99, 2009.
18. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated proitein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007. (Pubitemid 46763022)
19. Bader AG, Kang S, Zhao L, et al: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005. (Pubitemid 41766781)
20. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5): 1851-1857, 2009.
21. Prenen H, De Schutter J, Jacobs B, et al: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15: 3184-3188, 2009.
22. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762, 2010.
23. Jaiswal BS, Janakiraman V, Kljavin NM, et al: Somatic mutation in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474, 2009.
24. Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485, 2008.
25. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
26. Negri FV, Bozzetti C, Lagrasta CA, et al: PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102: 162-164, 2010.
27. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27(35): 5924-5930, 2009.
28. Jacobs B, De Roock W, Piessevaux H, et al: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30): 5068-5074, 2009.
29. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγR III a gene. Blood 99: 754-758, 2002. (Pubitemid 34525533)
30. Weng WK and Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947, 2003.
31. Kawaguchi Y, Kono K, Mimura K, et al: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma Int J Cancer 120: 781-787, 2007. (Pubitemid 46175397)
32. Kimura H, Sakai K, Arao T, et al: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98: 1275-1280, 2007. (Pubitemid 46993549)
33. Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of FcγR II a-FcγR III a polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129, 2009.
34. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20): 2040-2048, 2007. (Pubitemid 350106711)